earnings
confidence high
sentiment neutral
materiality 0.75
KalVista Q1 net loss $40.4M; FDA accepts NDA for sebetralstat, PDUFA June 17, 2025
KalVista Pharmaceuticals, Inc.
2025-Q1 EPS
reported -$0.87
vs consensus -$0.89
▲ beat
(+2.4%)
- Net loss $40.4M ($0.87/share) vs $25.3M prior year; no revenue recognized.
- Cash and securities $174.3M at July 31, down from $210.4M on April 30.
- FDA accepted NDA for oral sebetralstat for HAE; PDUFA goal date June 17, 2025.
- EMA validated MAA submission for sebetralstat; UK/Japan filings planned later in 2024.
- Phase 3 KONFIDENT-KID pediatric trial initiated dosing with oral disintegrating tablet.